

Since 2020, The Pharmaceutical Industry Has Spent Over \$205 Million In Fighting Against Lower Drug Prices For Consumers

Summary: The Inflation Reduction Act (IRA) and its [groundbreaking](#) provision allowing Medicare to negotiate lower drug prices for consumers [will head](#) to President Biden's desk in short order. This moment comes despite [intense industry opposition](#), with no opponent having [attacked](#) the legislation's drug negotiations as fervently as the pharmaceutical industry. Since 2020, the pharmaceutical industry, including, PhRMA, its allies, and the nation's largest pharmaceutical firms, have spent over \$205 million in multi-media ads and lobbying against efforts to lower drug prices for consumers:

- Over the year ending August 2022, PhRMA and its allies spent at least **\$57 million** on "[tv, cable, radio, and social media ads](#)" opposing Medicare drug price negotiations.
- Since the first quarter of 2020, PhRMA and the nation's largest pharmaceutical firms, including Pfizer, Johnson & Johnson, Eli Lilly, AbbVie, and Merck, have spent nearly **\$149 million** lobbying against legislation to lower drug costs.

Over The Last 12 Months, PhRMA And Its Allies Have Spent At Least \$57 Million On Ads Opposing Drug Pricing Legislation As Part Of Industry's Multi-Million Dollar Ad Blitz Against Lower Drug Prices.

PhRMA And Its Allies Have Spent At Least \$57 Million On "TV, Cable, Radio, And Social Media Ads Opposing Price Negotiations," Over The Last 12 Months.

Over The Year Ending August 2022, PhRMA And Its Allies Spent At Least \$57 Million On "TV, Cable, Radio, And Social Media Ads Opposing Price Negotiations," With \$19 Million Spent Since July 2022. "In the past 12 months, PhRMA and closely allied groups spent at least \$57 million — \$19 million of it since July — on TV, cable, radio, and social media ads opposing price negotiations, according to monitoring by the advocacy group Patients for Affordable Drugs. PhRMA spent over \$100 million this year to unleash a massive team of 1,500 lobbyists on Capitol Hill." [Kaiser Health News, [08/12/22](#)]

PhRMA Also Has A History Of Contributing To Industry Groups Fighting Prescription Drug Reform.

PhRMA Has Donated At Least \$75,000 To The 60 Plus Association, A "Right Alternative To The AARP," That Ran Ads In June 2022 Blasting Senator Joe Manchin For His Support Of Medicare Drug Negotiations.

June 2022: The 60 Plus Association, Which Considers Itself The "Right Alternative To The AARP," Ran Ads Against Senator Joe Manchin Over His Support Of Medicare Drug Negotiation, Stating He "Cracked Under Pressure" And Is Now "Supporting Biden's Devastating Plan To Strip \$300 Billion From Medicare, Leaving West Virginia Seniors With Even Fewer Treatments And Cures." "Joe [Manchin] cracked under pressure. Now he's supporting Biden's devastating plan to strip \$300 billion from Medicare, leaving West Virginia seniors with even fewer treatments and cures.' [...] The 60 Plus Association, which bills itself as the 'right alternative to the AARP,' is running this ad attacking Sen. Joe Manchin III (D-W.Va.) in heavy rotation on shows like 'Jeopardy.'" [Washington Post, [06/17/22](#)]

- **In 2019, The 60 Plus Association Received At Least \$75,000 From PhRMA.** “The group is not required to disclose its donors, but it has received substantial funds from organizations linked to the billionaire Koch family, according to a recent review of tax filings by the Center for Responsive Politics. (The organization says it has not received any contributions from anyone in the Koch network for well over a decade.) The Pharmaceutical Research and Manufacturers of America (PhRMA) reported contributing at least \$75,000 to the organization in 2019.” [Washington Post, [06/17/22](#)]

PhRMA Has Donated At Least \$78,500 To Americans For A Balanced Budget, Whose Associated Project, The Center For Innovation And Free Enterprise, Ran Ads Blasting The Inflation Reduction Act’s Provisions Lowering Drug Costs.

August 2022: The Center For Innovation And Free Enterprise, A “Project Of Americans For A Balanced Budget,” Ran Ads Blasting Congress For “Considering A Bill That Would Strip Nearly \$300 Billion In Medicare To Pay For Obamacare,” Harming The Research Of New Medications And Treatments. “Perhaps you’ve seen this TV ad, which has had me alternately laughing out loud and wanting to throw something at the screen — neither the most useful nor mature of responses. The smile fades. The camera pans down to her clutched, wrinkled hands as he continues, ‘Unfortunately, Congress is considering a bill that would strip nearly \$300 billion in Medicare to pay for Obamacare, and research on this treatment may be stopped.’ [...] Have they no shame? The ad was placed by an outfit called ‘Center for Innovation and Free Enterprise, a project of Americans for A Balanced Budget, Inc.’ about which little is known.” [Des Moines Register [Opinion], [08/13/22](#)]

- **In 2019, Americans For A Balanced Budget Received \$78,500 From PhRMA:**

(42) AMERICANS FOR A BALANCED BUDGET PO BOX 28091 RALEIGH, NC 27611	46-4576284	501(C)4	78,500
--	------------	---------	--------

[PhRMA 2019 990 via ProPublica, accessed [08/15/22](#)]

Since The Beginning Of 2020, PhRMA And Several Of The Largest Pharmaceutical Firms Have Spent Nearly \$150 Million Just Lobbying On Efforts To Lower Drug Costs - Part Of Over Half A Billion In Lobbying Spending Overall.

Over Just The Past Two Years, The Pharmaceutical Industry Has Spent Over \$545 Million Lobbying The Federal Government As It Fought To Defeat Efforts To Lower Drug Costs.

Over The Past Two Years, The Pharmaceutical Industry Has Spent Over \$545 Million Lobbying As It Fights Against Measures To Lower Drug Costs For Consumers. "And they are still fighting now. The pharmaceutical industry has spent more than \$545 million on lobbying over the past two years as it seeks to kill the effort to lower drug costs, plus millions more on television and digital ads through an array of nonprofit groups." [Huffington Post, [08/05/22](#)]

Since Q1 Of 2020, PhRMA Has Spent Over \$63.1 Million While Lobbying On Multiple Bills Aimed At Lowering The Costs Of Prescription Drugs.

Since January 2020, PhRMA Has Spent At Least \$63,160,000 While Lobbying The Federal Government On "H.R. 3 (Lower Drug Costs Now Act)" And Several Other Pieces Of Drug Pricing Legislation, Among Other Issues:

Quarter / Year	Client	Registrant	Activity	Amount
Q1 2022	PhRMA	PhRMA	"H.R. 3: Elijah E. Cummings Lower Drug Costs Now Act - Provisions related to prescription drug pricing, non-interference, and intellectual property H.R. 19: Lower Costs, More Cures Act of 2021 - Provisions related to prescription drugs H.R. 1976: Medicare for All Act of 2021 - Provisions related to Part D and non-interference H.R. 2071: Medicare Prescription Drug Price Negotiation Act of 2021 - Provisions related to Part D and non-interference H.R. 2139: Medicare Drug Price Negotiation Act - Provisions related to Part D and non-interference H.R. 2179: Affordable Insulin for the COVID-19 Emergency Act - Provisions related to Part D and insulin H.R. 4417: Capping Drug Costs for Seniors Act of 2021 - Provisions related to Part D and prescription drug pricing H.R. 5260: Reduced Costs and Continued Cures Act - Provisions related to prescription drug pricing and access"	\$8,070,000
Q4 2021	PhRMA	PhRMA	" H.R. 3: Elijah E. Cummings Lower Drug Costs Now Act - Provisions related to prescription drug pricing, non-interference, and intellectual property H.R. 19: Lower Costs, More Cures Act of 2021 - Provisions related to prescription drugs H.R. 1227: Medicare-X Choice Act of 2021 - Provisions related to Part D and non-interference H.R. 1976: Medicare for All Act of 2021 - Provisions related to Part D and non-interference H.R. 2071: Medicare Prescription Drug Price Negotiation Act of 2021 - Provisions related to Part D and non-interference H.R. 2139: Medicare Drug Price Negotiation Act - Provisions related to Part D and non-interference"	\$7,160,000

Q3 2021	PhRMA	PhRMA	<p>" H.R. 3: Elijah E. Cummings Lower Drug Costs Now Act - Provisions related to prescription drug pricing, non-interference, and intellectual property H.R. 19: Lower Costs, More Cures Act of 2021 - Provisions related to prescription drugs H.R. 1227: Medicare-X Choice Act of 2021 - Provisions related to Part D and non-interference H.R. 1976: Medicare for All Act of 2021 - Provisions related to Part D and non-interference H.R. 2010: Public Option Deficit Reduction Act - Provisions related to Part D and non-interference H.R. 2071: Medicare Prescription Drug Price Negotiation Act of 2021 - Provisions related to Part D and non-interference H.R. 2139: Medicare Drug Price Negotiation Act - Provisions related to Part D and non-interference H.R. 5260: Reduced Costs and Continued Cures Act - Provisions related to prescription drug pricing and access"</p>	\$7.440.000
Q2 2021	PhRMA	PhRMA	<p>" H.R. 3: Elijah E. Cummings Lower Drug Costs Now Act - Provisions related to prescription drug pricing, non-interference, and intellectual property H.R. 19: Lower Costs, More Cures Act of 2021 - Provisions related to prescription drugs H.R. 1167: Advancing Enrollment and Reducing Drug Costs Act of 2021 - Provisions related to Part D H.R. 1227: Medicare-X Choice Act of 2021 - Provisions related to Part D and non-interference H.R. 1976: Medicare for All Act of 2021 - Provisions related to Part D and non-interference H.R. 2010: Public Option Deficit Reduction Act - Provisions related to Part D and non-interference H.R. 2071: Medicare Prescription Drug Price Negotiation Act of 2021 - Provisions related to Part D and non-interference H.R. 2139: Medicare Drug Price Negotiation Act - Provisions related to Part D and non-interference H.R. 2868: Protecting Access to Affordable Medicines Act of 2021 - Provisions related to Medicaid and prescription drug pricing and rebates"</p>	\$6.430.000

Q1 2021	PhRMA	PhRMA	<p>" H.R. 3: Lower Drug Costs Now Act of 2019 [116th Congress]</p> <p>H.R. 19: Lower Costs, More Cures Act of 2019 [116th Congress]</p> <p>H.R. 1167: Advancing Enrollment and Reducing Drug Costs Act of 2021 - Provisions related to Part D</p> <p>H.R. 1227: Medicare-X Choice Act of 2021 - Provisions related to Part D and non-interference</p> <p>H.R. 1976: To establish an improved Medicare for All national health insurance program - Provisions related to Part D and non-interference</p> <p>H.R. 2010: To amend the Patient Protection and Affordable Care Act to establish a public health insurance option - Provisions related to Part D and non-interference</p> <p>H.R. 2071: To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate covered part D drug prices on behalf of Medicare beneficiaries - Provisions related to Part D and non-interference"</p>	\$8.540.000
Q4 2020	PhRMA	PhRMA	<p>"H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions</p> <p>H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions</p> <p>H.R. 8624: Protecting Access to Innovation During COVID-19 Act - Provisions related to Medicare and prescription drug pricing."</p>	\$5.130.000
Q3 2020	PhRMA	PhRMA	<p>"H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions</p> <p>H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions</p> <p>H.R. 1425: Patient Protection and Affordable Care Enhancement Act - Provisions related to affordability fund</p> <p>S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues</p> <p>S. 2543: Prescription Drug Pricing Reduction Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions</p> <p>S. 3129: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions</p> <p>S. 4199: Prescription Drug Pricing Reduction Act of 2020 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions."</p>	\$5.960.000

Q2 2020	PhRMA	PhRMA	"H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions H.R. 1425: Patient Protection and Affordable Care Enhancement Act - Provisions related to affordability fund S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543: Prescription Drug Pricing Reduction Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions."	\$5,410,000
Q1 2020	PhRMA	PhRMA	"H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions."	\$9,020,000
			TOTAL:	\$63,160,000

Since Q1 Of 2020, Pfizer Has Spent Over \$23.8 Million While Lobbying On "Drug Pricing," "Out-Of-Pocket Costs," And Related Issues.

Since January 2020, Pfizer Has Spent At Least \$23,860,000 While Lobbying The Federal Government On "Drug-Pricing," "Out-Of-Pocket Costs," And Related Issues:

Quarter / Year	Client	Registrant	Activity	Amount
Q1 2022	Pfizer Inc.	Pfizer Inc.	"Drug Pricing"	\$2,740,000
Q4 2021	Pfizer Inc.	Pfizer Inc.	"Drug Pricing"	\$2,980,000
Q3 2021	Pfizer Inc.	Pfizer Inc.	"Drug Pricing"	\$1,780,000
Q2 2021	Pfizer Inc.	Pfizer Inc.	"Drug Pricing"	\$2,330,000
Q1 2021	Pfizer Inc.	Pfizer Inc.	"Drug Pricing Biosimilars Drug Shortages Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Drug Importation"	\$3,160,000
Q4 2020	Pfizer Inc.	Pfizer Inc.	"Drug Pricing Biosimilars Drug Shortages Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Drug Importation"	\$2,380,000

Q3 2020	Pfizer Inc.	Pfizer Inc.	"Drug Pricing Biosimilars Drug Shortages Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Drug Importation"	\$1,930,000
Q2 2020	Pfizer Inc.	Pfizer Inc.	"Drug Pricing Biosimilars Drug Shortages Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Drug Importation"	\$2,470,000
Q1 2020	Pfizer Inc.	Pfizer Inc.	"Drug Pricing"	\$4,090,000
			TOTAL:	\$23,860,000

Since Q1 Of 2020, Johnson & Johnson Have Spent At Least \$13.9 Million Lobbying On "Drug Pricing Legislation," Including Build Back Better, "Elijah E. Cummings Lower Drug Costs Now Act," "H.R. 19/S. 2164, The Lower Costs, More Cures Act, S. 25430," "Prescription Drug Pricing Reduction Act Of 2019," Among Others.

Since January 2020, Johnson & Johnson Has Spent At Least \$13,950,000 Lobbying The Federal Government On "Drug Pricing Legislation," Including "H.R.3, Elijah E. Cummings Lower Drug Costs Now Act," "H.R. 5376, Build Back Better Act," And "Issues Related To The 340B Drug Discount Program," Among Other Issues:

Quarter / Year	Client	Registrant	Activity	Amount
Q1 2022	Johnson & Johnson Services Inc.	Johnson & Johnson Services Inc.	"- HR 3, 'Elijah E. Cummings Lower Drug Costs Now Act', regarding all provisions [...] - HR 5376, 'Build Back Better Act', regarding provisions on drug pricing and provisions related to revenue [...] - Issues related to prescription drug pricing [...] - Issues related to 340B drug pricing program"	\$2,320,000
Q4 2021	Johnson & Johnson Services Inc.	Johnson & Johnson Services Inc.	"- HR 5376, 'Build Back Better Act', regarding provisions on drug pricing and provisions related to revenue [...] - Issues related to prescription drug pricing [...] - Issues related to 340B drug pricing program - HR 3, 'Elijah E. Cummings Lower Drug Costs Now Act', regarding all provisions"	\$880,000
Q3 2021	Johnson & Johnson Services Inc.	Johnson & Johnson Services Inc.	"- HR 5376, 'Build Back Better Act', regarding provisions on drug pricing and provisions related to revenue [...] - Issues related to prescription drug pricing [...] - Issues related to 340B drug pricing program - HR 3, 'Elijah E. Cummings Lower Drug Costs Now Act', regarding all provisions"	\$1,920,000
Q2 2021	Johnson & Johnson Services Inc.	Johnson & Johnson Services Inc.	"- Issues related to prescription drug pricing - Issues related to health care pricing transparency [...] - Issues related to 340B drug pricing program"	\$800,000
Q1 2021	Johnson & Johnson Services Inc.	Johnson & Johnson Services Inc.	"- Issues related to prescription drug pricing - Issues related to health care pricing transparency [...] - Issues related to 340B drug pricing program"	\$2,480,000
Q4 2020	Johnson & Johnson Services Inc.	Johnson & Johnson Services Inc.	"- Issues related to the regulation of over-the-counter drugs [...] -- H.R. 3, 'Elijah E. Cummings Lower Drug Costs Now Act', regarding all provisions - Issues related to drug importation - S. 2543, 'Prescription Drug Pricing Reduction Act of 2019', regarding all provisions [...]"	\$1,450,000

			<ul style="list-style-type: none"> - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications -H.R. 133 - Consolidated Appropriations Act, 2021, including legislation regarding average sales price (ASP) reporting requirements for certain hyaluronic acid (HA) products that are classified as devices, but reimbursed as drugs under Medicare Part B." 	
Q3 2020	Johnson & Johnson Services Inc.	Johnson & Johnson Services Inc.	<ul style="list-style-type: none"> "- Issues related to the regulation of over-the-counter drugs [...] - H.R. 3, 'Elijah E. Cummings Lower Drug Costs Now Act', regarding all provisions - Issues related to drug importation - S. 2543, 'Prescription Drug Pricing Reduction Act of 2019', regarding all provisions [...] - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications" 	\$860,000
Q2 2020	Johnson & Johnson Services Inc.	Johnson & Johnson Services Inc.	<ul style="list-style-type: none"> "- Issues related to the regulation of over-the-counter drugs [...] - H.R. 3, 'Elijah E. Cummings Lower Drug Costs Now Act', regarding all provisions - Issues related to drug importation - S. 2543, 'Prescription Drug Pricing Reduction Act of 2019', regarding all provisions 	\$1,760,000
Q1 2020	Johnson & Johnson Services Inc.	Johnson & Johnson Services Inc.	<ul style="list-style-type: none"> "- Issues related to the regulation of over-the-counter drugs [...] - H.R. 3, 'Elijah E. Cummings Lower Drug Costs Now Act', regarding all provisions - Issues related to drug importation - S. 2543, 'Prescription Drug Pricing Reduction Act of 2019', regarding all provisions 	\$1,480,000
TOTAL:				\$13,950,000

Since Q1 Of 2020, Eli Lilly Has Spent At Nearly \$14 Million Lobbying On "Drug Pricing, Value And Access," Including "H.R. 3, The Lower Drug Costs Now Act," "Affordable Prescriptions For Patients Act Of 2021," And "H.R. 5376 - Build Back Better Act, Subtitle J (Part B And D Drug Pricing)."

Since January 2020, Eli Lilly Has Spent At Least \$13,945,000 Lobbying The Federal Government On "Drug Pricing, Value And Access," Including "H.R. 5376 - Build Back Better Act, Subtitle J (Part B And D Drug Pricing);" "H.R. 3, The Lower Drug Costs Now Act," "Affordable Prescriptions For Patients Act Of 2021 (S 1435 & HR.2873)," Among Other Issues:

Quarter / Year	Client	Registrant	Activity	Amount
Q1 2022	Eli Lilly & Company	Eli Lilly & Company	"Drug pricing, value and access [...] 'Build Back Better' (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833)"	\$1,510,000

Q4 2021	Eli Lilly & Company	Eli Lilly & Company	"Drug supply chain and shortages; Drug pricing, value and access; Transparency [...] Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)"	\$2,180,000
Q3 2021	Eli Lilly & Company	Eli Lilly & Company	"Drug supply chain and shortages; Drug pricing, value and access; Transparency [...] Drug importation; Prescription drug value and access; Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873)."	\$1,320,000
Q2 2021	Eli Lilly & Company	Eli Lilly & Company	"Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; [...] Drug importation; Prescription drug value and access"	\$1,675,000
Q1 2021	Eli Lilly & Company	Eli Lilly & Company	"Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; [...] Medicare & Medicaid prescription drug reimbursement, coverage and value; Prescription Drug Pricing Reduction Act (PDPRA - S.4199); [...] Drug importation; Prescription drug value and access"	\$1,840,000
Q4 2020	Eli Lilly & Company	Eli Lilly & Company	"drug supply chain and shortages; Drug pricing, value and access [...] Drug importation; Prescription drug value and access [...]Prescription Drug Pricing Reduction Act (PDPRA) (S. 4199)"	\$950,000
	Eli Lilly & Company	Eli Lilly & Company	"Drug pricing [...] Prescription Drug Pricing Reduction Act (PDPRA)(S.4199)"	\$1,450,000
Q2 2020	Eli Lilly & Company	Eli Lilly & Company	"drug supply chain and shortages; Drug pricing and value; Transparency; [...]Medicare & Medicaid prescription drug reimbursement and value; Prescription Drug Pricing Reduction Act (PDPRA)(S.4199);"	\$1,730,000
Q1 2020	Eli Lilly & Company	Eli Lilly & Company	"Drug supply chain and shortages; Drug pricing and value; [...] Medicare & Medicaid prescription drug reimbursement and value; Prescription Drug Pricing Reduction Act (PDPRA)"	\$1,290,000
TOTAL:				\$13,945,000

Since Q1 Of 2020, AbbVie Has Spent At Least \$16.7 Million Lobbying On "Drug Cost And Pricing Policy Issues," Including "Including H.R.3, The Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164," "The Lower Costs, More Cures Act," And "H.R.5376, The Build Back Better Act."

Since January 2020, AbbVie Has Spent At Least \$16,710,000 Lobbying The Federal Government On "Drug Cost And Pricing Policy Issues," Including ""H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act," "H.R. 19, Lower Costs, More Cures Act," And "H.R. 5376, The Build Back Better Act," Among Other Issues:

Quarter / Year	Client	Registrant	Activity	Amount
Q1 2022	AbbVie Inc.	AbbVie Inc.	"H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act H.R. 19, Lower Costs, More Cures Act H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5801, Help Ensure Lower Patient Copays Act S. 2164, Lower Costs, More Cures Act of 2021 Drug cost and pricing policy issues"	\$3,980,000
Q4 2021	AbbVie Inc.	AbbVie Inc.	"H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act - all H.R. 19, Lower Costs, More Cures Act - all H.R. 5260, Reduced Costs and Continued Cures Act - all H.R. 5801, Help Ensure Lower Patient Copays Act - all S. 2164, Lower Costs, More Cures Act of 2021 - all Drug cost and pricing policy issues"	\$1,290,000
Q3 2021	AbbVie Inc.	AbbVie Inc.	"H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act - all H.R. 19, Lower Costs, More Cures Act - all"	\$1,940,000

			H.R. 5260, Reduced Costs and Continued Cures Act - all S. 2164, Lower Costs, More Cures Act of 2021 - all Drug cost and pricing policy issues Patient affordability issues"	
Q2 2021	AbbVie Inc.	AbbVie Inc.	"H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act H.R. 19, Lower Costs, More Cures Act S. 2164, Lower Costs, More Cures Act of 2021 Drug cost and pricing policy issues Patient affordability issues"	\$680,000
Q1 2021	AbbVie Inc.	AbbVie Inc.	"H.R. 2007: The Stephanie Tubbs Jones Uterine Fibroid Research And Education Act Of 2021 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues"	\$3,090,000
Q4 2020	AbbVie Inc.	AbbVie Inc.	"H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647, To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage 340B drug discount program policy issues Drug cost and pricing policy issues [...] H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues	\$650,000
Q3 2020	AbbVie Inc	AbbVie Inc.	"H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage. 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues [...] H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions H.R. 19: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895: Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates	\$1,430,000

			S. 3129: Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13938, White House Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing"	
Q2 2020	AbbVie Inc	AbbVie Inc.	"H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues [...] S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements"	\$670,000
Q1 2020	AbbVie Inc	AbbVie Inc.	"H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues H.R. 6201, Families First Coronavirus Response Act - provisions related to health care 340B drug discount program policy issues Drug cost and pricing policy issues [...] H.R. 3, Lower Drug Costs Now Act of 2019 - Provisions related to non-interference, International Pricing Index Model and Medicare Part D H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues H.R. 6201, Families First Coronavirus Response Act - provisions related to health care 340B drug discount program policy issues Drug cost and pricing policy issues"	\$2,980,000
TOTAL:				\$16,710,000

Since January 2020, Merck & Co., Inc. Has Spent At Least \$17.1 Million On Lobbying Against Initiatives Aimed At Lowering The Costs Of Prescription

Drugs, Including "H.R. 3 Elijah E. Cummings Lower Costs Now Act," "H.R. 19 Lower Costs, More Cures Acts Of 2021," "H.R. 5376 Build Back Better Act," And Other Legislation.

Since January 2020, Merck Has Spent At Least \$17,110,000 Lobbying The Federal Government On Policies Aimed At Lowering The Costs Of Prescription Drugs, Including "H.R. 3 Elijah E. Cummings Lower Costs Now Act," "H.R. 19 Lower Costs, More Cures Acts Of 2021," "H.R. 5376 Build Back Better Act," And Other Legislation:

Quarter / Year	Client	Registrant	Activity	Amount
Q1 2022	Merck & Co., Inc.	Merck & Co., Inc.	"H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting;"	\$2,120,000
Q4 2021	Merck & Co., Inc.	Merck & Co., Inc.	" H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019; H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019; S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019."	\$1,500,000
Q3 2021	Merck & Co., Inc.	Merck & Co., Inc.	"H.R. 5376, Build Back Better Act; S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019; S. 1895 (116th Congress) Lower Health Care Costs Act; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting."	\$1,700,000
Q2 2021	Merck & Co., Inc.	Merck & Co., Inc.	"H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019."	\$1,220,000
Q1 2021	Merck & Co., Inc.	Merck & Co., Inc.	"H.R. 3, (116th Congress) Lower Drug Costs Now Act of 2019 H.R. 19 (116th Congress) Lower Costs, More Cures Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act 340 drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting."	\$3,590,000
Q4 2020	Merck & Co., Inc.	Merck & Co., Inc.	"H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 19, Lower Costs, More Cures Act of 2019."	\$1,210,000
Q3 2020	Merck & Co., Inc.	Merck & Co., Inc.	" H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing, S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019."	\$980,000
Q2 2020	Merck & Co., Inc.	Merck & Co., Inc.	"H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act; S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019."	\$2,620,000
Q1 2020	Merck & Co., Inc.	Merck & Co., Inc.	"H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019."	\$2,170,000
TOTAL:				\$17,110,000

